Netherlands· NL-69ceae68fd61
Nemluvio 30 mg poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde pen
A nemolizumab product containing nemolizumab, registered in Netherlands by Galderma International. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Nemolizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AH12 (nemolizumab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Nemolizumab · ATC D11AH12
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nemolizumab costs, country by country.
Normalised to the WHO defined daily dose (0.8 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nemolizumab · price per daily dose (0.8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$67.16
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- NEMOLIZUMAB
- Manufacturer
- Galderma International
- Country
- Netherlands (NL)
- ATC code
- D11AH12
- ATC class
- Nemolizumab
- Defined daily dose
- 0.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1901
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nemolizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandNemluvio 30 mg powder and solvent for solution for injection in pre-filled penGalderma International
- FranceNEMLUVIO 30 mg, poudre et solvant pour solution injectable en stylo prérempliGALDERMA INTERNATIONAL
- CzechiaNEMLUVIOGalderma International, La Défense
- SwitzerlandNemluvio 30 mg, Pulver und Lösungsmittel für Injektionslösung im FertigpenGalderma SA
- BelgiumNemluvio 30 mgGalderma International
- IcelandNemluvioGalderma International
- Japanネモリズマブ(遺伝子組換え)マルホ
- PolandNemluvioGalderma International
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nemluvio
- Liechtenstein · Nemluvio
- Norway · Nemluvio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5b3d4e78-c938-4006-9ee7-534031abbcd0 GET /v1/drugs/5b3d4e78-c938-4006-9ee7-534031abbcd0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Poeder en oplosmiddel voor oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/nemluvio-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Nemolizumab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp132885",
"excipients": [
"ARGININEHYDROCHLORIDE, (L-)",
"POLOXAMEER 188",
"SACCHAROSE",
"TROMETAMOL",
"TROMETAMOLHYDROCHLORIDE",
"WATER VOOR INJECTIE"
],
"substances": [
"NEMOLIZUMAB"
],
"leaflet_url": null,
"authorised_at": "2025/02/12",
"procedure_number": "EMEA/H/C/006149",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1901",
"additional_monitoring": "Y"
}See everything about nemolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.